Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS).

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Brucella* ; Vaccines* ; Brucellosis*/prevention & control; Animals ; Humans ; Type IV Secretion Systems ; Epitopes, B-Lymphocyte ; Molecular Docking Simulation ; Epitopes, T-Lymphocyte ; Computational Biology/methods ; Vaccines, Subunit

Brucellosis is a common zoonosis, which is caused by Brucella infection, and Brucella often infects livestock, leading to abortion and infertility. At present, human brucellosis remains one of the major public health problems in China. According to previous research, most areas in northwest China, including Xinjiang, Tibet, and other regions, are severely affected by Brucella. Although there are vaccines against animal Brucellosis, the effect is often poor. In addition, there is no corresponding vaccine for human Brucellosis infection. Therefore, a new strategy for early prevention and treatment of Brucella is needed. A multi-epitope vaccine should be developed. In this study, we identified the antigenic epitopes of the Brucella type IV secretion system VirB8 and Virb10 using an immunoinformatics approach, and screened out 2 cytotoxic T lymphocyte (CTL) epitopes, 9 helper T lymphocyte (HTL) epitopes, 6 linear B cell epitopes, and 6 conformational B cell epitopes. These advantageous epitopes are spliced together through different linkers to construct a multi-epitope vaccine. The silico tests showed that the multi-epitope vaccine was non-allergenic and had a strong interaction with TLR4 molecular docking. In immune simulation results, the vaccine construct may be useful in helping brucellosis patients to initiate cellular and humoral immunity. Overall, our findings indicated that the multi-epitope vaccine construct has a high-quality structure and suitable characteristics, which may provide a theoretical basis for the development of a Brucella vaccine.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Yin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. (PMID: 29788355)
Microorganisms. 2022 Aug 10;10(8):. (PMID: 36014038)
J Genet Eng Biotechnol. 2021 May 11;19(1):69. (PMID: 33974183)
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S3-23. (PMID: 20176265)
Front Immunol. 2022 Feb 18;13:806825. (PMID: 35250977)
Microorganisms. 2022 Aug 06;10(8):. (PMID: 36014002)
BMC Vet Res. 2022 Sep 7;18(1):337. (PMID: 36071517)
Genome Res. 2003 Dec;13(12):2665-73. (PMID: 14656971)
Front Immunol. 2021 Aug 12;12:668492. (PMID: 34456902)
J Biomol Struct Dyn. 2022 May;40(8):3416-3427. (PMID: 33200673)
Microbiol Mol Biol Rev. 2021 Feb 10;85(1):. (PMID: 33568459)
J Invest Dermatol. 1984 Jul;83(1 Suppl):121s-127s. (PMID: 6376646)
PLoS Med. 2007 Dec;4(12):e317. (PMID: 18162038)
J Virol. 2001 Jan;75(2):654-60. (PMID: 11134279)
Int J Med Microbiol. 2003 Jun;293(2-3):213-7. (PMID: 12868658)
Mol Immunol. 2017 Nov;91:65-74. (PMID: 28886588)
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W271-6. (PMID: 24771341)
Immunol Res. 1998;18(2):79-92. (PMID: 9844827)
Front Immunol. 2019 Dec 03;10:2776. (PMID: 31849959)
Front Immunol. 2019 Feb 26;10:298. (PMID: 30863406)
Clin Microbiol Infect. 2005 Aug;11(8):632-6. (PMID: 16008615)
Front Cell Infect Microbiol. 2015 Oct 13;5:72. (PMID: 26528442)
Front Immunol. 2020 Apr 07;11:442. (PMID: 32318055)
BMC Bioinformatics. 2013;14 Suppl 4:S2. (PMID: 23514126)
J Proteome Res. 2020 Jun 5;19(6):2304-2315. (PMID: 32308001)
Sci Rep. 2022 Jun 16;12(1):10146. (PMID: 35710873)
Chem Sci. 2016 Feb 1;7(2):842-854. (PMID: 28791117)
Science. 2021 Aug 20;373(6557):871-876. (PMID: 34282049)
Bioengineering (Basel). 2023 Mar 28;10(4):. (PMID: 37106617)
J Immunol Res. 2017;2017:2680160. (PMID: 29445754)
Mol Microbiol. 2009 Feb;71(3):779-94. (PMID: 19054325)
Sci Rep. 2022 Mar 17;12(1):4645. (PMID: 35301360)
Mol Microbiol. 1998 Jan;27(2):405-14. (PMID: 9484895)
FASEB J. 2021 Mar;35(3):e21409. (PMID: 33577115)
Front Cell Infect Microbiol. 2012 Apr 19;2:35. (PMID: 22919627)
Int J Pept Res Ther. 2021;27(2):1469-1480. (PMID: 33679273)
Vaccines (Basel). 2021 Sep 26;9(10):. (PMID: 34696187)
Vaccine. 2020 Apr 29;38(20):3671-3681. (PMID: 32247566)
Lancet Infect Dis. 2006 Feb;6(2):91-9. (PMID: 16439329)
PLoS One. 2010 Nov 04;5(11):e13458. (PMID: 21079793)
Int J Mol Sci. 2021 Dec 20;22(24):. (PMID: 34948430)
J Virol. 1993 Jul;67(7):4415-20. (PMID: 8389938)
Immune Netw. 2015 Apr;15(2):51-7. (PMID: 25922593)
Int J Pept Res Ther. 2021;27(2):941-956. (PMID: 33192207)
Sci Rep. 2019 Feb 21;9(1):2517. (PMID: 30792446)
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454. (PMID: 32406916)
BMC Public Health. 2016 Aug 22;16(1):853. (PMID: 27549329)
Nucleic Acids Res. 2017 Jul 3;45(W1):W365-W373. (PMID: 28521030)
Clin Dev Immunol. 2012;2012:925135. (PMID: 22474485)
Vet Res. 2021 Jun 2;52(1):75. (PMID: 34078437)
Biosci Rep. 2019 Jun 28;39(6):. (PMID: 31196965)
Methods Mol Biol. 2009;524:427-38. (PMID: 19377963)
Biochim Biophys Acta. 2013 Nov;1833(11):2392-402. (PMID: 23481039)
Comput Biol Med. 2016 Sep 1;76:24-9. (PMID: 27393958)
J Clin Diagn Res. 2016 Apr;10(4):DC24-7. (PMID: 27190804)
Cell Mol Immunol. 2018 Feb;15(2):182-184. (PMID: 28890542)
Biochem Cell Biol. 2006 Dec;84(6):890-9. (PMID: 17215876)
Sci Rep. 2018 Jun 13;8(1):9044. (PMID: 29899345)
Sci Rep. 2019 Mar 5;9(1):3512. (PMID: 30837598)
Cold Spring Harb Perspect Med. 2013 May 01;3(5):a012476. (PMID: 23637311)
Recent Pat Antiinfect Drug Discov. 2013 Apr;8(1):34-41. (PMID: 22873352)
Mol Microbiol. 2006 Apr;60(2):480-92. (PMID: 16573696)
J Biomol Struct Dyn. 2023 Jan 26;:1-15. (PMID: 36703619)
Bioinformatics. 2009 Sep 1;25(17):2200-7. (PMID: 19549632)
Microb Pathog. 2021 Oct;159:105150. (PMID: 34425197)
Trop Med Health. 2020 Oct 20;48:86. (PMID: 33093792)
Vet World. 2018 Aug;11(8):1030-1036. (PMID: 30250359)
Bioinformatics. 2009 May 1;25(9):1189-91. (PMID: 19151095)
BMC Bioinformatics. 2010 Aug 18;11:431. (PMID: 20718988)
Sci Rep. 2020 Apr 14;10(1):6368. (PMID: 32286356)
Biotechnol Adv. 2012 Sep-Oct;30(5):1102-7. (PMID: 21968145)
PLoS One. 2013;8(1):e52773. (PMID: 23382822)
Infect Genet Evol. 2017 Apr;49:309-317. (PMID: 28185986)
Infect Dis Poverty. 2020 May 24;9(1):55. (PMID: 32448394)
FEBS Lett. 2015 Jul 8;589(15):1883-9. (PMID: 26071378)
Protein Sci. 2003 Aug;12(8):1652-62. (PMID: 12876315)
Biomed Res Int. 2018 Apr 22;2018:5712920. (PMID: 29850535)
Immunogenetics. 2010 Jun;62(6):357-68. (PMID: 20379710)
Epidemiol Infect. 2021 May 25;149:e136. (PMID: 34032200)
PLoS One. 2010 Apr 16;5(4):e9862. (PMID: 20419125)
PLoS One. 2016 May 19;11(5):e0155340. (PMID: 27195765)
Nat Immunol. 2001 May;2(5):415-22. (PMID: 11323695)

0 (Type IV Secretion Systems)
0 (Epitopes, B-Lymphocyte)
0 (Vaccines)
0 (Epitopes, T-Lymphocyte)
0 (Vaccines, Subunit)

Date Created: 20230810 Date Completed: 20230814 Latest Revision: 20230814

20240829

PMC10414599

10.1371/journal.pone.0286358

37561685